JP2020522495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522495A5 JP2020522495A5 JP2019566156A JP2019566156A JP2020522495A5 JP 2020522495 A5 JP2020522495 A5 JP 2020522495A5 JP 2019566156 A JP2019566156 A JP 2019566156A JP 2019566156 A JP2019566156 A JP 2019566156A JP 2020522495 A5 JP2020522495 A5 JP 2020522495A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- lag
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111618A JP2023126946A (ja) | 2017-05-30 | 2023-07-06 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| JP2026001835A JP2026062993A (ja) | 2017-05-30 | 2026-01-08 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512618P | 2017-05-30 | 2017-05-30 | |
| US62/512,618 | 2017-05-30 | ||
| US201762513812P | 2017-06-01 | 2017-06-01 | |
| US62/513,812 | 2017-06-01 | ||
| PCT/US2018/035125 WO2018222711A2 (en) | 2017-05-30 | 2018-05-30 | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111618A Division JP2023126946A (ja) | 2017-05-30 | 2023-07-06 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522495A JP2020522495A (ja) | 2020-07-30 |
| JP2020522495A5 true JP2020522495A5 (https=) | 2021-07-26 |
Family
ID=62751546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566156A Pending JP2020522495A (ja) | 2017-05-30 | 2018-05-30 | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| JP2023111618A Pending JP2023126946A (ja) | 2017-05-30 | 2023-07-06 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| JP2026001835A Pending JP2026062993A (ja) | 2017-05-30 | 2026-01-08 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111618A Pending JP2023126946A (ja) | 2017-05-30 | 2023-07-06 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| JP2026001835A Pending JP2026062993A (ja) | 2017-05-30 | 2026-01-08 | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20210340250A1 (https=) |
| EP (2) | EP4245375A3 (https=) |
| JP (3) | JP2020522495A (https=) |
| KR (1) | KR20200010500A (https=) |
| CN (1) | CN110691795A (https=) |
| AU (2) | AU2018277559A1 (https=) |
| BR (1) | BR112019018759A2 (https=) |
| CA (1) | CA3060989A1 (https=) |
| IL (1) | IL269090A (https=) |
| MX (1) | MX2019012038A (https=) |
| WO (1) | WO2018222711A2 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| SMT202300418T1 (it) | 2017-05-30 | 2024-01-10 | Bristol Myers Squibb Co | Trattamento di tumori positivi per lag-3 |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| CA3066053A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN111491665B (zh) * | 2017-09-26 | 2024-08-06 | 中外制药株式会社 | 药物组合物 |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| MX2021000726A (es) * | 2018-07-26 | 2021-03-25 | Bristol Myers Squibb Co | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. |
| AU2019405950A1 (en) * | 2018-12-20 | 2021-07-15 | Biotie Therapies, Inc. | Methods for treating cancer using tozadenant |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| EP3906415B1 (en) * | 2019-01-03 | 2026-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| KR20220008316A (ko) * | 2019-05-14 | 2022-01-20 | 에프-스타 테라퓨틱스 리미티드 | Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CA3153777A1 (en) * | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| TR202005738A1 (tr) * | 2020-04-10 | 2021-10-21 | Hacettepe Ueniversitesi Rektoerluek | Küçük hücreli̇ akci̇ğer kanseri̇nde cd44+ cd90+ kanser kök hücreleri̇ni̇n i̇ndükledi̇ği̇ tim-3 ve lag-3 reseptörünün hedeflenmesi̇ |
| CN113616788A (zh) * | 2020-05-08 | 2021-11-09 | 勤浩医药（苏州）有限公司 | 抗lag-3抗体与shp-2抑制剂联合治疗肿瘤的用途 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
| US11970533B2 (en) * | 2020-06-18 | 2024-04-30 | Sparx Bioscience Limited | Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1) |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| EP4274852A4 (en) * | 2021-01-11 | 2025-02-26 | Eutilex Co., Ltd. | BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| US20240181052A1 (en) * | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| US20240287199A1 (en) * | 2021-06-18 | 2024-08-29 | Alligator Bioscience Ab | Novel combination therapies and uses thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| JP2024535793A (ja) * | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用 |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| US20250002600A1 (en) | 2021-10-06 | 2025-01-02 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| TW202413412A (zh) | 2022-05-12 | 2024-04-01 | 丹麥商珍美寶股份有限公司 | 在組合療法中能夠結合到ｃｄ２７之結合劑 |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| CN115845052B (zh) * | 2022-12-28 | 2023-12-29 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗结肠癌中的应用 |
| CN115869399B (zh) * | 2022-12-28 | 2024-01-12 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
| CN121620391A (zh) | 2023-04-06 | 2026-03-06 | 金麦安博股份有限公司 | 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂 |
| CN116925236B (zh) * | 2023-05-12 | 2024-06-04 | 上海恩凯细胞技术有限公司 | 嵌合转换受体及其应用 |
| CN121285385A (zh) | 2023-05-12 | 2026-01-06 | 金麦安博股份有限公司 | 能够与ox40结合的抗体、其变体及其用途 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025195358A1 (zh) * | 2024-03-19 | 2025-09-25 | 江苏恒瑞医药股份有限公司 | Pd-1结合蛋白及医药用途 |
| WO2025207936A1 (en) * | 2024-03-28 | 2025-10-02 | Mirror Biologics, Inc. | Treatment for colorectal cancer using immune checkpoint inhibitors |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| BR112013026828A2 (pt) | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
| CN113461819B (zh) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EA037554B1 (ru) | 2013-03-15 | 2021-04-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Анти-lag-3 связывающие белки |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| SG11201601763SA (en) * | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| WO2015082499A2 (en) | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CA2939164A1 (en) | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
| US20150259420A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| JP2017507983A (ja) | 2014-03-18 | 2017-03-23 | アイティーオス セラペウティクス | 新規な３−インドール置換誘導体、医薬組成物、および使用方法 |
| NZ725860A (en) | 2014-04-04 | 2019-08-30 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| PE20170247A1 (es) | 2014-05-15 | 2017-03-29 | Iteos Therapeutics | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| RU2719446C2 (ru) | 2014-11-03 | 2020-04-17 | Айомет Фарма Лтд | Фармацевтическое соединение |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| KR20170072343A (ko) * | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| EP3546473B1 (en) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016147144A1 (en) | 2015-03-17 | 2016-09-22 | Pfizer Inc. | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| US10945994B2 (en) | 2015-05-14 | 2021-03-16 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| CA2993177A1 (en) | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017025498A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| EP3334733A1 (en) | 2015-08-10 | 2018-06-20 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CA3002236A1 (en) | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| WO2017087901A2 (en) | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| AU2017266298B2 (en) | 2016-05-18 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti PD-1 and anti-LAG3 antibodies for cancer treatment |
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| KR102664891B1 (ko) | 2016-06-20 | 2024-05-13 | 에프-스타 테라퓨틱스 리미티드 | Pd-l1 및 lag-3에 결합하는 결합 분자 |
| CA3024359A1 (en) | 2016-06-23 | 2017-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
| EP3498840A4 (en) | 2016-08-15 | 2020-05-06 | National University Corporation Hokkaido University | ANTI-LAG-3 ANTIBODY |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| MY203971A (en) | 2016-10-13 | 2024-07-26 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| WO2018083087A2 (en) | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Binding proteins |
-
2018
- 2018-05-30 US US16/616,569 patent/US20210340250A1/en not_active Abandoned
- 2018-05-30 CN CN201880036532.7A patent/CN110691795A/zh active Pending
- 2018-05-30 MX MX2019012038A patent/MX2019012038A/es unknown
- 2018-05-30 BR BR112019018759A patent/BR112019018759A2/pt unknown
- 2018-05-30 EP EP23174625.6A patent/EP4245375A3/en active Pending
- 2018-05-30 WO PCT/US2018/035125 patent/WO2018222711A2/en not_active Ceased
- 2018-05-30 AU AU2018277559A patent/AU2018277559A1/en not_active Abandoned
- 2018-05-30 KR KR1020197038188A patent/KR20200010500A/ko not_active Withdrawn
- 2018-05-30 JP JP2019566156A patent/JP2020522495A/ja active Pending
- 2018-05-30 CA CA3060989A patent/CA3060989A1/en active Pending
- 2018-05-30 EP EP18734678.8A patent/EP3630842A2/en not_active Withdrawn
-
2019
- 2019-09-03 IL IL26909019A patent/IL269090A/en unknown
-
2022
- 2022-08-10 US US17/818,838 patent/US20230111786A1/en not_active Abandoned
-
2023
- 2023-07-06 JP JP2023111618A patent/JP2023126946A/ja active Pending
-
2025
- 2025-01-16 US US19/025,264 patent/US20250163152A1/en active Pending
- 2025-03-31 AU AU2025202283A patent/AU2025202283A1/en active Pending
-
2026
- 2026-01-08 JP JP2026001835A patent/JP2026062993A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522495A5 (https=) | ||
| US20250163152A1 (en) | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent | |
| US20220098302A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| JP2020522691A5 (https=) | ||
| JP6970099B2 (ja) | ガンの処置のための方法及び医薬組成物 | |
| US20240066040A1 (en) | Ep4 inhibitors and use thereof | |
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2018027952A5 (https=) | ||
| JP2017537892A5 (https=) | ||
| JP2016525117A5 (https=) | ||
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| JP7458973B2 (ja) | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 | |
| KR102946586B1 (ko) | Lag-3 길항제 요법에 대한 정량적 공간 프로파일링 | |
| TW201828985A (zh) | 在抗pd-l1/pd1治療失敗後以抗csf-1r抗體與抗pd-l1抗體之組合進行腫瘤之治療 | |
| JP2020522541A (ja) | 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法 | |
| JP2024511106A (ja) | Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法 | |
| CN110709420A (zh) | 使用抗gitr抗体的癌症组合疗法 | |
| JP2024507866A (ja) | Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法 | |
| JPWO2021040056A5 (https=) | ||
| RU2020143572A (ru) | Противораковая композиция, содержащая опухолеспецифический онколитический аденовирус и ингибитор контрольной точки иммунного ответа | |
| EA051733B1 (ru) | Композиции, содержащие комбинацию анти-lag-3 антитела, ингибитора сигнального пути pd-1 и иммунотерапевтического средства | |
| JPWO2022189978A5 (https=) |